Efficacy, effectiveness, immunogenicity - are not the same in vaccinology

Aleksandra Banaszkiewicz, Andrzej Radzikowski

Abstract

Manuscript of Carrera et al is devoted to immunization in inflammatory bowel disease (IBD) that is very important issue in gastroenterology. However, some specific definitions used in the article need clarification. Efficacy of vaccine is measured in a randomised, placebo-controlled studies, that are expensive and difficult to plan. Moreover, it is unethical to offer a placebo instead of vaccine. For all of these reasons, efficacy of vaccine is measured in IBD patients rarely. Effectiveness of vaccine is measured as an epidemiological affect from observational studies. These studies are also uncommon in IBD because it would be difficult to perform a study that assess the prevalence of one rare disease (vaccine-preventable) in patients with a chronic rare condition, such as IBD. Immunogenicity of vaccine refers to the ability of a vaccine to induce an immune response in a vaccinated individual that is, in fact, the matter of the article.

TO THE EDITOR

We read with interest the manuscript of Carrera et al

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Efficacy; Effectiveness; Immunogenicity; Vaccine

Core tip: The Carrera et al’s article presents some important issues regarding immunisation in inflammatory bowel disease patients. However, in our opinion, definition of vaccine efficacy is misused. In fact this article is on vaccine immunogenicity. Here, we emphasise the differences between the definitions of efficacy, effectiveness and immunogenicity, differences that are fundamental in vaccinology.
to as effectiveness. Apart from ethical and economic considerations, it would be difficult to perform a study that assessed the prevalence of one rare disease (vaccine-preventable) in patients with a chronic rare condition, such as IBD. The efficacy of a vaccine may indirectly predict cases of that one rare disease when the protecting level of antibodies is known from previous epidemiological studies. Immunogenicity refers to the ability of a vaccine to induce an immune response (antibody- and/or cell-mediated immunity) in a vaccinated individual. Until now, neither efficacy nor effectiveness has been assessed in IBD patients for any vaccine. All of the vaccine studies in IBD patients have instead assessed the immunogenicity of the vaccines.

Proper use of these terms is not just an academic issue, as the level of antibodies does not always predict real protection against a disease. Immunogenicity can be low, as observed in hepatitis B virus vaccine (i.e., in the Gisbert et al study, only 36% of IBD patients on immunosuppressive and biological therapy achieved adequate hepatitis B surface antibody levels), but hepatitis B cases are extremely rare in a vaccinated IBD population.

REFERENCES

1 Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol 2013; 19: 1349-1353 [PMID: 23538553 DOI: 10.3748/wjg.v19.i9.1349]
2 Centers for Disease Control and Prevention. Evaluating Influenza Vaccine Efficacy and Effectiveness Studies. Published for the 2010-11 Influenza Season; Adapted for the 2012-13 Influenza Season. Available from: URL: http://www.cdc.gov/flu/professionals/acip/evaluating.htm
3 Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-1466 [PMID: 22934605 DOI: 10.1038/ajg.2012.79]

P- Reviewers: Chen W, Kanda T, Moss AC  S- Editor: Ma YJ  L- Editor: A  E- Editor: Ma S
